News · Money Today·

Canopy Therapeutics: 'Bispecific antibody ADC shows excellent anti-tumor efficacy and tolerability'

Predicted impact: Low· Actual: −3.3% vs sector, volume 4.3× normal (5 trading days)

Same ADC anti-tumor efficacy data already reported in the last 14 days; no new size.

Comments

Sign in to comment

No comments yet. Start the conversation.

Comments are people's own views. Nothing here is financial advice.